PAM
CTMX icon

Panagora Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Panagora Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-114,014
Closed -$209K – 1452
2022
Q2 		$209K Buy
114,014
+9
+0% +$17 ﹤0.01% 1399
2022
Q1 		$304K Buy
114,005
+1,072
+0.9% +$4.12K ﹤0.01% 1354
2021
Q4 		$489K Buy
112,933
+117
+0.1% +$685 ﹤0.01% 1224
2021
Q3 		$574K Buy
112,816
+19,123
+20% +$102K ﹤0.01% 1250
2021
Q2 		$593K Buy
93,693
+71,000
+313% +$553K ﹤0.01% 1257
2021
Q1 		$175K Sell
22,693
-75,788
-77% -$600K ﹤0.01% 1753
2020
Q4 		$645K Sell
98,481
-173,252
-64% -$1.24M ﹤0.01% 1135
2020
Q3 		$1.81M Sell
271,733
-88,867
-25% -$659K 0.01% 693
2020
Q2 		$3M Buy
360,600
+8,016
+2% +$74.4K 0.02% 539
2020
Q1 		$2.7M Sell
352,584
-129,953
-27% -$906K 0.02% 508
2019
Q4 		$4.01M Buy
+482,537
New +$3.26M 0.02% 547
2019
Q2 		– Sell
-65,159
Closed -$700K – 2621
2019
Q1 		$700K Sell
65,159
-23,371
-26% -$345K ﹤0.01% 1274
2018
Q4 		$1.34M Sell
88,530
-91,709
-51% -$1.36M 0.01% 951
2018
Q3 		$3.33M Sell
180,239
-35,509
-16% -$809K 0.01% 654
2018
Q2 		$4.93M Buy
215,748
+56,734
+36% +$1.45M 0.02% 530
2018
Q1 		$4.52M Sell
159,014
-28,643
-15% -$818K 0.02% 572
2017
Q4 		$3.96M Buy
187,657
+61,767
+49% +$1.28M 0.01% 622
2017
Q3 		$2.29M Hold
125,890
– – 0.01% 812
2017
Q2 		$1.95M Buy
125,890
+125,834
+224,704% +$1.9M 0.01% 870
2017
Q1 		$1K Buy
+56
New +$737 ﹤0.01% 2343

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Panagora Asset Management's CTMX Position: Q3 2022 in Review

Panagora Asset Management sold out of CytomX Therapeutics (CTMX) in Q3 2022, closing a stake of 114,014 shares — an estimated $209K sold.

Panagora Asset Management first reported a position in CTMX in Q1 2017 and held it in 20 quarters. The position peaked at $4.93M in Q2 2018. 84 funds tracked by Wall St. Rank hold CTMX as of Q3 2022.

  • Panagora Asset Management reported no remaining CytomX Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Panagora Asset Management sold 114,014 CytomX Therapeutics shares in Q3 2022, an estimated $209K.
  • Panagora Asset Management first reported a position in CytomX Therapeutics in Q1 2017 and held it in 20 quarters.
  • Panagora Asset Management's CytomX Therapeutics position peaked at $4.93M in Q2 2018.
  • 84 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2022.

Based on Panagora Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.